Telemedycyna Polska is a telemedicine provider offering medical consultations, heart diagnostics, cardiac care, and its own round-the-clock alarm centre.
Who does it compete with for the same buyer, and how do they differ?
Telemedycyna Polska and Pro-PLUS both serve healthcare providers seeking remote cardiac diagnostics, yet they differ in delivery: Telemedycyna Polska equips medical facilities with devices and software that forward examinations to its Telemedicine Center for remote reporting, whereas Pro-PLUS pairs certified TeleEKG devices with its CardioScp WEB telemedicine platform covering remote diagnosis, monitoring and supervision of patients with cardiovascular diseases and other chronic conditions.
Telemedycyna Polska reports ECG examination results in an average of several minutes and Holter examinations in up to 24 hours.
2Memo
What is the investment case, and what must be true for it to hold?
Telemedycyna Polska can improve its results as cost reductions support progress, provided service growth and cost discipline continue, with staffing capacity and IT the main risks to that condition. Sales and equivalent revenue were 5.166,1 tys. zł in 2025, down 0.7% from 2024. Operating costs fell 11.9% to 6.517,2 tys. zł in 2025.
Telemedycyna Polska S.A. recorded EBITDA of 17,7 tys. zł during the first quarter of 2026.
3Product Overview
What does the product do for its buyer, and how is it delivered?
Telemedycyna Polska lets medical facilities route Holter and ECG examinations to a remote specialist service by supplying devices and software that send each examination directly to its Telemedicine Center for reporting; Pro-PLUS is an alternative offering remote monitoring and diagnosis through certified TeleEKG devices and a telemedicine platform.
Pro-PLUS also delivers telemedical supervision, operating through its CardioScp WEB platform.
